Pharma Mar (OTCMKTS:PHMMF – Get Free Report) was upgraded by Chardan Capital to a “strong-buy” rating in a report issued on Thursday, Zacks.com reports.
Pharma Mar Stock Performance
Shares of PHMMF stock opened at $34.26 on Thursday. Pharma Mar has a 52-week low of $26.85 and a 52-week high of $46.26. The company has a current ratio of 2.63, a quick ratio of 2.22 and a debt-to-equity ratio of 0.14. The stock has a fifty day simple moving average of $32.89 and a two-hundred day simple moving average of $33.95.
About Pharma Mar
Featured Stories
- Five stocks we like better than Pharma Mar
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Most Effectively Use the MarketBeat Earnings Screener
- MarketBeat Week in Review – 7/29 – 8/2
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.